August 2, 2018
A retrospective chart review of 38 patients with MEN2B evaluated at the National Institutes of Health, with 21% of patients developing pheochromocytoma in the 10.5 year follow up period.
The study concludes that undiagnosed PHEO can be associated with substantial morbidity. Current American Thyroid Association guidelines recommend PHEO screening starting at age 11 for the high-/highest risk group. The youngest patient diagnosed with PHEO in our cohort was an asymptomatic 10-year-old, suggesting that PHEO development may begin before the screening-recommended age of 11, though remains clinically undetectable and thus the current screening guidelines seem appropriate.